Summary
A retrospective study was performed on 69 breast cancer patients (stage II, N=18; advanced disease, N=51) in order to assess the prognostic value of circulating prolactin (PRL), CEA, CA 15-3, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF) by RIA/IRMA. These markers were compared with short-term prognosis (two years). Significant difference was observed only for PRL (<20.0 ng/ml vs. >20.0 ng/ml), which provide an independent predictor of short-term prognosis in advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 8:1233–1240, 1989
McGuire WL: Steroid receptors in human breast cancer. Cancer Res 38:4289–4291, 1978
Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989
Toi M, Nakamura H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980–1984, 1990
Gullick WJ, Berger MS, Bannett PLP, Rothbard JB, Waterfield MD: Expression of the c erb B2 protein in normal and transformed cells. Int J Cancer 40: 246–254, 1987
Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 16:3–13, 1990
Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63:2139–2147, 1989
Bhatavdekar JM, Giri DD, Shah NG, Trivedi SN, Patel DD, Karelia NH, Balar DB, Bhaduri A, Vora HH, Ghosh N, Shukla MK: Prolactin in advanced breast carcinoma — An Indian experience. Breast Disease 3:199–204, 1990
Bhatavdekar JM, Shah NG, Balar DB, Patel DD, Bhaduri A, Trivedi SN, Karelia NH, Ghosh N, Shukla MK, Giri DD: Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 65:2028–2032, 1990
Bhatavdekar JM, Patel DD, Giri DD, Shah NG, Karelia NH, Vora HH, Trivedi SN, Ghosh N, Suthar TP, Balar DB: Plasma prolactin and prognosis in advanced breast cancer. Breast Disease 6:107–111, 1993
International Union against Cancer. TNM classification of malignant tumors. UICC technical report series 51, 1980
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377, 1957
Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958
Schmidt-Rhode P, Schulz KD, Sturm G, Raab-Frick A, Prinz H: CA 15.3 as a tumor marker in breast cancer. Int J Biol Markers 2:135–142, 1987
Bhatavdekar JM, Balar DB, Shah NG, Trivedi SN, Bhaduri A, Patel DD, Karelia NH, Shukla MK, Ghosh N: Prognosis in breast carcinoma utilizing plasma carcinoembryonic antigen and histologic characteristics of the primary tumor. Tumor Biol 8:233–240, 1987
Bhatavdekar JM, Trivedi SN, Shah NG, Patel DD, Karelia NH, Shukla MK, Ghosh N, Vora HH: Comparison of prolactin, CA 15-3 and TPA in breast carcinomas. Int J Biol Markers 4:150–156, 1989
Wang DY, Hamed H, Mockridge CI, Fentiman IS: Radioimmunoassayable insulin-like growth factor-1 in human breast cystic fluid. Eur J Cancer Clin Oncol 25:867–872, 1989
Boccardo F, Torrisi R, Zanardi S, Valenti G, Pensa F, De Franchis V, Barreca A, Ferraro P, Minuto F: EGF in breast cyst fluid: Relationship with intracystic androgens, estradiol and progesterone. Int J Cancer 47:523–526, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhatavdekar, J., Patel, D., Karelia, N. et al. Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study. Breast Cancer Res Tr 30, 293–297 (1994). https://doi.org/10.1007/BF00665970
Issue Date:
DOI: https://doi.org/10.1007/BF00665970